Related Experiment Videos
Prophylactic oral UFT therapy for superficial bladder cancer
Y Kubota1, M Hosaka, S Fukushima
1Department of Urology, Yokohama City University, School of Medicine, Japan.
Cancer
|March 1, 1993
Summary
Long-term oral UFT therapy significantly reduced superficial bladder cancer recurrence. This oral treatment offers an effective strategy for preventing cancer regrowth after surgery.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Superficial bladder cancer frequently recurs after treatment.
- Preventing intravesical recurrence is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of long-term oral UFT (tegafur/uracil) in preventing superficial bladder cancer recurrence.
- To assess the safety and tolerability of UFT therapy in this context.
Main Methods:
- A randomized prospective trial involving 112 patients with newly diagnosed superficial bladder transitional cell carcinoma (Ta, T1, G1-G2).
- Patients were randomized to receive either 2 years of oral UFT (300-400 mg/day) or a control regimen.
- Follow-up was conducted to monitor intravesical recurrence rates.
Main Results:
- The UFT group showed a significantly lower recurrence rate (25.7%) compared to the control group (43.3%) after a median follow-up of 24.5 months (P=0.015).
- Adverse events associated with UFT administration were found to be acceptably low.
Conclusions:
- Long-term oral UFT administration following transurethral resection is an effective strategy for preventing the recurrence of superficial bladder cancer.
- UFT therapy presents a viable option for adjuvant treatment in managing superficial bladder tumors.